GlaxoSmithKline Seeks Variation of Authorization for Anemia Treatment
13 November 2014 - 9:05AM
Dow Jones News
LONDON-- GlaxoSmithKline PLC (GSK.LN) Wednesday said it has
submitted a request to the European Medicines Agency for a
variation to the marketing authorization for its anemia treatment
eltrombopag after conducting two studies on the treatment.
Shares at 1312 GMT, up 1 pence, or 0.7%, at 1,441 pence valuing
the company at GBP70 billion.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024